deltatrials
Completed PHASE3 INTERVENTIONAL NCT00378417

Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes

Efficacy Trial in Finnish Children of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Pneumococcal Serotypes in the Vaccines

Sponsor: Finnish Institute for Health and Welfare

Conditions Otitis Media Pneumococcal Infections
Interventions 7-valent pneumococcal-CRM197 conjugate vaccine 7-valent pneumococcal-OMPC conjugate vaccine
Updated 6 times since 2017 Last updated: Sep 19, 2006 Started: Mar 31, 1995 Completion: Mar 31, 1999
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Otitis Media and Pneumococcal Infections and is currently completed. Finnish Institute for Health and Welfare leads this study, which shows 6 recorded versions since 1995 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Sep 2020 · 44 months · monthly snapshotCompleted~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotCompleted~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshotCompleted~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE3

  5. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Sep 2020 [monthly]

    Completed PHASE3

    First recorded

Mar 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Finnish Institute for Health and Welfare
  • Merck Sharp & Dohme LLC
  • Pasteur Merieux Connaught
  • Wyeth-Lederle Vaccines
Data source: Finnish Institute for Health and Welfare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations